Global Cholera Vaccines market overview: Cholera vaccines are given orally to aid in preventing the spread of the cholera virus. The vaccine contains live, weakened strains of the Vibrio cholerae bacteria, which causes cholera. Once administered, the vaccine strains multiply in the intestines and induce protection without causing illness. Cholera often strikes in areas with poor sanitation and limited access to clean water. It causes acute watery diarrhea and can kill within hours if untreated.

The Global Cholera Vaccines Market is estimated to be valued at US$ 82.5 MN in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Cholera Vaccines are Sanofi, Biovac.co.za., EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD. Sanofi's oral cholera vaccine Dukoral is the leading vaccine in many regions. Biovac has an oral multi-strain vaccine approved for use in Africa and South America.

The growing demand for Cholera Vaccines Market Growth is driven by increasing global outbreaks of the disease. Between 2010-2019, over 1.3 million cases of cholera were reported to WHO from 58 countries. Recurring outbreaks across Africa, Asia, and Haiti underscore the ongoing need for vaccination campaigns in vulnerable areas.

Increasing numbers of manufacturers are expanding the geographic availability and supply of effective cholera vaccines. Valneva, EpiVax, and others are working to develop lower-cost second-generation vaccines that provide broad coverage of cholera strains and longer-lasting immunity. Expanding production capacity in emerging markets will help control future outbreaks.

Market drivers

Increasing global awareness about cholera prevention is driving demand for vaccination. International organizations like WHO recommend vaccination for high-risk populations in endemic areas and during outbreaks. Enhanced surveillance systems now enable more timely identification and response to cholera cases worldwide. Government stockpiling of oral cholera vaccines also facilitates rapid deployment when outbreaks emerge. Continued education efforts will be crucial to sustaining vaccination programs over the long run.